Skip to main content
Log in

Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors

  • Research Article
  • Published:
Inflammopharmacology Aims and scope Submit manuscript

Abstract.

Cyclooxygenase-2 (COX-2) is known to suppress sporadic colorectal cancer, but effect of selective COX-2 inhibitor in UC-associated neoplasia is still unknown. This study investigated effect of a selective COX-2 inhibitor on colorectal carcinogenesis in experimental murine UC. Chronic colitis was induced in mice by four cycles of administration of dextran sulfate sodium (DSS) (i. e., 5 % DSS for 7 days and distilled water for the following 14 days), and the mice were sacrificed 120 days after the end of the fourth cycle. The mice were divided into the following five groups: Group A, served as a disease control; Group B, received a diet mixed with 400 ppm of nimesulide (NIM), a selective COX-2 inhibitor, during the whole period; Group C, received NIM during the four cycles of DSS administration; Group D, received NIM for 120 days from the end of the fourth cycle; Group E, served as a normal control. In Group D, NIM significantly suppressed the occurrence of dysplasia and/or cancer. The results show that NIM inhibited both dysplasia and cancer in DSS-treated mice, thus showing that NIM has preventive effects on the remission phase of carcinogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to T. Inoue.

Additional information

Received 20 July 2006; revised 21 August 2006; accepted 4 September 2006

Rights and permissions

Reprints and permissions

About this article

Cite this article

Inoue, T., Hirata, I. & Murano, M. Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors. Inflammopharmacol 16, 36–39 (2008). https://doi.org/10.1007/s10787-006-1543-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10787-006-1543-3

Keywords:

Navigation